Background. Cortical stimulation (CS) combined with rehabilitation may improve upper limb motor function after stroke. Objective. Describe the study design for the Everest Clinical Trial, a randomized single-blinded pivotal device trial, testing safety and efficacy of epidural CS delivered during rehabilitation for upper limb motor function in patients with ischemic stroke. Method. A total of 174 participants from 21 centers with hemiplegia at least 4 months after acute ischemic stroke are randomized in a 2:1 ratio to investigational or control groups. Investigational patients undergo implantation of cortical electrode and pulse generator and receive 6 weeks of upper limb rehabilitation with subthreshold CS delivered only during therapy. Control group patients receive the same therapy without device implantation or stimulation. Primary outcome measures include the upper extremity Fugl-Meyer (UEFM) score and the arm motor ability test (AMAT) measured at baseline and 1, 4, 12, and 24 weeks following rehabilitation treatment with primary endpoint at 4 weeks following treatment. A successful outcome is defined as an improvement in UEFM of at least 4.5 points and in AMAT of at least 0.21 points from baseline to primary endpoint. A 20% better success rate between investigational and control groups will be considered clinically meaningful. Adverse events occurring during the study will be identified. Results. Not applicable. Conclusions. The Everest Clinical Trial is the first randomized pivotal trial on the safety and efficacy of direct CS delivered during rehabilitation for recovery of upper limb motor function in patients with ischemic stroke.
F or survivors, stroke causes significant functional limitations in mobility and upper limb use and severely restricts community participation. Neurological recovery of hemiplegia improves for both arm and leg over the first 8 weeks following stroke, 1 but improvement in upper limb function is far more limited than recovery of walking ability. More than 90% of stroke survivors will achieve functional walking with or without an assistive device within 6 months of stroke. 2 In contrast, only 30% to 66% will regain functional arm use in the same time period and less than 20% achieve complete recovery. 3 With the prevalence of stroke in the United States at 5.7 million, an estimated 2.8 million people with stroke have limited or absent function of their upper limb. 4 The public health impact of upper limb hemiplegia after stroke is therefore significant.
Current clinical evidence suggests that motor relearning after stroke is best facilitated by rehabilitation that provides challenging and functionally oriented task practice. 5, 6 Neuroplastic changes in cerebral cortex have been noted following specific rehabilitation protocols in both animal models of ischemic injury as well as in human stroke survivors. 7 Similar neuroplastic processes are also seen following intracortical microstimulation of motor cortex in rats, 8 raising the possibility that cortical brain stimulation might facilitate rehabilitation outcomes and enhance motor performance after stroke in humans.
Noninvasive methods of cortical stimulation (CS) include repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS). Targeted rTMS can produce changes in cortical excitability for a brief period following stimulation. Low-frequency rTMS (<1 Hz) decreases cortical excitability, and high-frequency rTMS (>5 Hz) produces increases in cortical excitability. Long repetitive trains with higher stimulation frequencies above motor threshold result in longer periods of enhanced cortical excitability following rTMS. For example, trains of suprathreshold rTMS at 20 Hz result in an increase in cortical excitability lasting up to 3 to 4 minutes. [9] [10] [11] Enhanced cortical excitability can be induced with subthreshold rTMS as well, though it requires longer trains of stimulation (240 pulses or more). [12] [13] [14] [15] Similarly, tDCS can increase cortical excitability by delivering a weak polarizing direct electrical current through the cranium. Five minutes of anodal stimulation over M1 cortex at 0.2 to 1 mA increases cortical excitability for up to 5 minutes after stimulation. In contrast, cathodal stimulation of M1 reduces cortical excitability. 16 Applying tDCS for 13 minutes can enhance excitability for up to 1.5 hours following stimulation. 17, 18 Presently, the cortical effects of rTMS and tDCS have not induced long-term improvement in motor performance. Small clinical trials in chronic stroke patients using high-frequency rTMS over the ipsilesional hemisphere or low-frequency rTMS over the contralesional hemisphere demonstrate that CS can improve finger dexterity, 19 pinch, 20 and reaction time 21, 22 of the affected hand. Multiple sessions of CS produce longer lasting improvements in motor performance than a single session, 21, 23 but no trial has tested performance beyond 2 weeks after treatment. Two clinical trials of tDCS show similar findings with transient improvement of upper limb performance both during, and for 20 minutes following, stimulation. 24, 25 Although the preliminary data on the noninvasive forms of CS such as rTMS and tDCS are encouraging, their potential use in a clinical setting are limited by the extensive setup necessary, the amount of equipment required, and the tedious manipulation needed to consistently target the same area of cortex within and across sessions. One solution to this problem is to deliver CS via an implanted epidural electrode and implantable pulse generator (IPG). In addition to the advantage of a firmly fixed electrode, efficacy might be enhanced by providing long trains of subthreshold CS during motor training. Several trials in rat and nonhuman primate stroke models using such a strategy demonstrate that targeted CS combined with motor retraining can result in faster and more complete recovery of motor performance with concomitant evidence of neuroplastic changes. [26] [27] [28] [29] Two recent randomized feasibility studies of ipsilesional motor cortex CS to improve upper limb motor recovery in human stroke survivors have been conducted using an investigational implanted epidural bipolar electrode and an external pulse generator (n = 8) 30 or a fully implanted electrode, lead and pulse generator (n = 24). 31 Patients receiving CS combined with rehabilitation targeting the impaired upper limb showed clinically relevant improvement on the upper extremity Fugl-Meyer (UEFM) score, whereas control subjects receiving rehabilitation alone showed only minimal change. Neither of these feasibility studies was powered to test for efficacy, but rather, they were designed to assess safety and provide pilot data for the design of a pivotal trial. Both studies showed that implanted CS could be applied safely and suggested sufficient efficacy to warrant a larger multicenter study.
Based on the results of these feasibility studies, a large, statistically powered, multicenter study was designed to test for efficacy of the device combined with therapy: the Everest Clinical Trial.
The specific aim of the Everest Trial is to assess the effects of subthreshold stimulation to the primary motor cortex by an epidural electrode and implanted pulse generator delivered only during rehabilitation therapy. This study is appropriately powered to demonstrate both the safety and efficacy of CS therapy to enhance upper limb motor function in patients with ischemic stroke. In addition to testing efficacy and safety of CS, this study uses magnetic resonance imaging (MRI) and functional MRI (fMRI) to guide electrode placement and repeats imaging after rehabilitation to monitor therapy-induced functional reorganization. The hypothesis is that patients with stroke assigned to the investigational group that receive CS in conjunction with upper limb rehabilitation will more likely achieve clinically meaningful improvement of motor control and function compared with a similar cohort of stroke patients assigned to the control group that receives only rehabilitation. In addition, this large study adds further safety data to that previously collected from the 2 earlier feasibility studies.
Study Design
The Everest Clinical Trial is a prospective, randomized, single-blinded, multicenter comparison study of the safety and efficacy of targeted epidural CS delivered in conjunction with intensive task-oriented functional motor retraining of the impaired upper limb in patients with ischemic stroke. Patients are randomized at a ratio of 2:1 to an investigational group receiving CS and rehabilitation or to a control group receiving rehabilitation alone. The unequal randomization scheme allowed more investigational than control patients so that sufficient safety data could be acquired regarding the surgical and CS procedures.
The primary outcome measurements for this study assess clinically meaningful changes in both impairment and function of the affected arm and hand after therapy. The primary efficacy endpoint for comparison is 4 weeks after completion of the rehabilitation treatment. Secondary measures including motor, cognitive, and communication outcomes are also assessed using various standardized tests of neurological impairment, functional activities, participation, and quality of life. Clinical measures are tested up to 24 weeks after treatment to determine long-term efficacy.
The study examines the safety of epidural CS as an intervention as well as the safety of device implantation and explantation, including the surgical procedure, anesthesia, postoperative care, and wound healing. Thus, the control subjects do not receive a sham surgical procedure or device implantation. The study is powered to detect with 95% confidence adverse events that have at least a 3% probability of occurrence.
Participants
Up to 174 patients with stroke are anticipated to participate in the Everest Trial, randomized in a 2:1 ratio of investigational group to control, respectively, based on the sample size determination as described later. Study candidates must be more than 21 years of age with a history of ischemic stroke causing impairment and limited use of the contralesional upper limb. Before entering the study, candidates are required to be at least 4 months from stroke ictus to assure that the upper limb impairment will be stable, as demonstrated in longitudinal studies by Duncan et al. 32 The stroke can be either cortical or subcortical, but above the level of the midbrain, and be documented on cranial computed tomography or MRI. The qualifying ischemic lesion must be the cause of the upper limb neurological impairment. Patients must have some paralysis of the affected upper limb as measured by a score between 28 and 50 (inclusive) on the UEFM test. The inclusion criteria are listed in Table 1 .
Patients are excluded from participation if they have had an intracerebral hemorrhage. Those with a primary ischemic stroke and some secondary petechial hemorrhage with residual tissue hemosiderin can be included. Patients with other neurological conditions contributing to upper limb motor impairment, such as Parkinson's disease, multiple sclerosis, or peripheral nerve injury, are excluded. Those with another symptomatic stroke in addition to the stroke causing arm impairment are also excluded. In contrast, patients with asymptomatic ischemic lesions noted on cranial imaging in addition to the stroke of interest can be included. A history of late seizures occurring more than 1 month after the stroke or any history of status epilepticus are criteria for exclusion. A complete list of exclusion criteria are detailed in Table 2 .
Procedures
The study procedures and management of human subjects was approved by each site's institutional review board.
Study Enrollment and Rehabilitation Screening
All participants review and sign an informed consent at the time of enrollment as required by individual site institutional review board. Each patient is then screened for all inclusion and exclusion criteria as listed in Tables 1 and 2 . If inclusion/exclusion criteria are passed, a brief rehabilitation assessment by a trained study occupational or physical therapist is conducted to determine if the patient is able to understand and perform upper limb motor tasks necessary for the functional brain imaging (fMRI) and rehabilitation protocols (described in subsequent sections). Inability to understand or perform these tasks will exclude the patient from the study. 
Brain Imaging Protocol
A structural and functional magnetic resonance brain imaging (MRI and fMRI) procedure is performed to verify the anatomical location of the stroke and to identify the cortical area of functional activation ipsilesional to the stroke within the primary motor cortex that is associated with voluntary movement of the affected hand. This location was selected based on success with use of CS in animal models with focal cortical injury where the electrode was targeted over ipsilesional motor cortex. [26] [27] [28] [29] Once identified, the activation site near ipsilesional primary motor cortex is targeted with neuronavigation as a site for epidural electrode placement in patients who are later randomized to the investigational group.
Imaging studies are performed using commercially available whole-body high-speed MRI scanners with 1.5-T or greater magnets. Structural images include a 3-dimensional volumetric data set, high-resolution T1-weighted anatomical scans, and, optionally, diffusion weighted imaging and diffusion tensor imaging.
To complete the fMRI protocol, patients are required to perform 1 of 4 hand/wrist activities with the affected upper limb. These include tapping of the index finger, simultaneous tapping of 4 fingers, repetitive wrist extension, or repetitive full hand grasping. The best of these 4 tasks that the patient can readily perform is selected for the fMRI procedure, where imaging is conducted using a block design that alternates active task performance and no movement. Participants are instructed to lie supine in the scanner and perform the selected task on cue from the technician.
Patients are monitored continuously during the imaging procedure by direct auditory contact and, in most cases, visual observation as well. If a patient experiences claustrophobia, they are removed from the scanner and evaluated by the site investigator. Anxiolytic medications may be prescribed at physician discretion. The total imaging procedure should last no more than 1.5 hours. Images are processed by a study investigator using a regression analysis contrasting images during motor activity with images at rest. Assessments with excess head motion are discarded.
Using the fMRI images, the study investigators visually select an activation site over the lateral convexity and peri-Rolandic region correlated with contralesional hand and wrist movement. If an activation site cannot be identified, the fMRI procedure may be repeated after the patient ingests a caffeinated drink, such as coffee or tea, to enhance the BOLD response. If despite these efforts an activation site cannot be clearly identified within the ipsilesional motor cortex, the patient is excluded from the study. In addition, inability to tolerate the brain imaging procedures due to claustrophobia, excessive movement during imaging, or the presence of mirror movement in the unaffected upper limb during motor task performance may also constitute reasons for exclusion from the study.
Once satisfactory images have been obtained, they are transferred to a stereotaxic neuronavigation system whereupon the surgical and cortical sites for electrode placement are projected for use by the neurosurgeon.
Other Baseline Evaluations
Following brain imaging, participants undergo a series of baseline measures and medical evaluations. These include a complete medical history, physical and neurological examination, blood tests (eg, blood count, chemistries, and pregnancy test), electrocardiogram, and chest X-ray. Patients are excluded from further study participation if the medical and neurological evaluations reveal any exclusionary conditions listed in Table 2 , such as significant medical instability or pregnancy.
Standardized measures collected in this study are listed in Table 3 . These include assessments of upper limb impairment and motor control, functional limitations, cognitive ability, and quality of life. All standardized measures are collected once at baseline with the exception of the UEFM, which is collected twice prior to randomization. If the 2 UEFM scores are within 3 points, then the baseline UEFM score is recorded as the average of the 2 scores. If, however, the 2 UEFM scores are greater than 3 points different, a third measure of UEFM is collected on a subsequent testing day. In this circumstance the baseline UEFM score is the median of the 3 scores. The same method of assessing the UEFM scores 2 to 3 times is also applied at the primary endpoint 4 weeks following treatment. The use of the mean or median score of 2 or 3 measures of UEFM reduces the measurement error that can occur with single assessments of UEFM and assures a more accurate measure of arm and hand impairment at baseline and follow-up.
Randomization
Randomization occurs after completion of baseline activities in a site-specific block design such that up to 110 patients will be assigned to the investigational treatment group and up to 64 to the control group. Randomization blocks are computer generated with random block size blinded to the local clinical investigators. Patients randomized to the control group do not undergo stimulation system implantation procedures nor receive CS. Both groups participate in 6 weeks of the same rehabilitation protocol.
Surgical Procedure
Those patients randomized to the investigational group undergo stimulation system implantation. All antiplatelet or anticoagulant agents are withheld up to 14 days prior to surgery and resumed 1 to 3 days after. Perioperative platelet count <100 000 or prolonged prothombin or partial thromboplastin time are corrected prior to surgery. Unless contraindicated, all patients receive prophylactic antibiotics preoperatively.
Under general anesthesia, skin is shaved and prepped for a simple extradural craniotomy exposure above the predetermined area of cortex, as guided by frameless stereotaxic neuronavigation. Following craniotomy and exposure of the dura mater, the stimulation electrode is placed over the dural surface with the lead wire oriented perpendicular to the central sulcus and then anchored with suture. Following this the dura is examined for any damage or tears and repaired as necessary with suture material or with tissue grafts from the patients' own temporalis fascia or pericranium. The investigational stimulation system is manufactured by Northstar Neuroscience, Inc (Seattle, WA) and is approved for use in the Everest Clinical Trial by the US Food and Drug Administration under an investigational device exemption. The sterile, single-use stimulation electrodes have 6 contacts configured in a flexible 2 × 3 element array. One row of 3 contacts is configured as anodes, and the opposite 3 elements are configured as cathodes in reference to the first phase of the stimulation waveform.
Using standard surgical techniques, the lead is tunneled beneath the scalp and skin of the neck behind the ear and connected to a subclavicularly-located neurostimulation equivalent of an IPG. The stimulation system's in vivo impedance is tested to ensure electrical continuity of the device system. The incision wounds are then irrigated and sutured closed.
Patients remain in hospital overnight following device implantation. The surgical site is observed for wound healing and signs of infection. Superficial wound infections are treated with appropriate antibiotic therapy and an adverse event is reported. If a deeper or persistent infection were to occur, the device would be completely removed, the wounds irrigated and debrided, followed by appropriate oral or intravenous antibiotic therapy and adverse event reporting. These patients would then be excluded from further participation in the study.
Patients are released from hospital to a family member or caregiver and provided with implant information, including an implant identification card and a patient's manual. Patients return in approximately 1 week for a wound check and suture removal.
Threshold Testing and Adjustment of Stimulator Output
After implantation and prior to treatment, investigational patients have the stimulator current output adjusted to 50% of movement threshold. These adjustments are made during threshold testing with a study physician present. During testing the patient will sit upright in a chair with both arms at rest. The IPG is programmed via telemetry to provide bipolar pulses of 250 µs duration at a frequency of 50 Hz. The current is sequentially increased until movement is observed in the patient's contralateral face, arm, or hand. The stimulator output is set to a current at 50% of the threshold current. If no movement is evoked by maximum IPG output, the current is set at 50% of maximum output, which is 6.5 mA. Within these defined parameters, the investigational patients should not experience involuntary motor activity, sensations, or seizures during stimulation.
Stimulation Protocol
During rehabilitation treatment, patients randomized to the investigational group receive targeted subthreshold CS. The stimulation is initiated 5 minutes prior to the start of each rehabilitation session via telemetry by placing a handheld wand over the IPG. Stimulation is terminated at the end of the session and is not delivered between rehabilitation therapy sessions. A study physician or nurse is immediately available on-site at all times during CS treatment.
Stimulation output is not adjusted during the rehabilitation protocol; however, if the patient experiences involuntary movement or sensations during treatment, the IPG current is reduced until such symptoms resolve.
Rehabilitation Protocol
Both investigational and control patients begin rehabilitation treatment approximately 2 to 4 weeks following randomization. Just before initiating rehabilitation therapy, the UEFM is repeated. The rehabilitation protocol is then administered in a standardized fashion over 6 weeks, providing a total of approximately 2.5 hours of treatment on each therapy day divided into 2 daily sessions. Therapy is delivered 5 days a week for the first 4 weeks and then 3 days a week for the later 2 weeks. Thus, a total of 26 therapy days are provided, amounting to 65 treatment hours. Investigational patients receive CS during rehabilitation, whereas control patients receive rehabilitation alone.
All treating therapists must undergo an initial certification and receive a passing score allowing them to deliver a standardized rehabilitation protocol and must recertify their competence in the protocol techniques every 6 months for the duration of the trial. The protocol is based on the contemporary task-oriented approach (also known as systems model of motor control) as described by Bass-Haugen et al. 43 It applies the principles of motor control research to occupational therapy, emphasizing the role of the environment and its interaction with the person performing the task. The model explains motor behavior as the interplay between the individual's motor abilities, the task requirement, and the environment. The focus of the therapy is targeted to the hemiplegic upper limb, but does not exclude bimanual activities. For practical application of task-oriented therapy, the therapist must have an adequate understanding of the movement patterns required for a particular task as well as the individual's motor patterns that may interfere with successful task performance. In collaboration with the patient, the therapist helps solve the motor problem by manipulating the structure of the task to be performed, by remediation of the patients impairment (eg, improve scapular alignment and stability or improve functional reach) or by changing environmental variables such as using equipment like a built-up grip.
Because functional upper limb movement requires coordination of shoulder, elbow, and distal joints, a sequence of prefunctional and functional activities that address components of upper limb movement and use are presented to the patient. The focus of these therapeutic activities is primarily on distal movements because cortical electrode placement is targeted over cortex that is active during hand and wrist motion. If, however, the patient has challenges with proximal arm stability affecting distal hand function, some portion of the therapy sessions can be used to address proximal motor control. Functional movements such as grasp, release, and reach are emphasized. In addition, activities of daily living (ADL) are practiced including self-care and other tasks that are meaningful to the patient and require the affected upper limb. The sequence of activities performed in a daily session is presented in Table 4 . On completion of the 6-week protocol, patients are provided with exercises to continue at home, at the discretion of the patient and therapist.
Although patients are expected to participate in all 26 sessions, a missed therapy session does not influence subsequent study participation. Study investigators instruct patients not to participate in additional physical or occupational therapy during the 6-week rehabilitation protocol or during the 4-week follow-up period.
Stimulation System Removal
Approximately 8 weeks after completion of the rehabilitation protocol, patients in the investigational group have the stimulation system removed. Antiplatelet and anticoagulant agents are stopped up to 14 days prior to surgery and resumed 1 to 3 days following surgery as clinically indicated. Postoperative care and wound management are as previously described. Patients then return approximately 1 week after surgery for wound check and suture removal.
Assessment of Outcome
Both primary and secondary outcome measures are listed in Table 3 . Assessments are taken at 1, 4, 12, and 24 weeks after completing rehabilitation treatment. The first assessment posttreatment was set at 1 week after treatment to avoid the influence of fatigue on the quality of performances that may occur immediately following the rigorous rehabilitation training program. Each site in the Everest study employs a single rater for assessment of upper limb performance. Raters are trained by and tested prior to data collection and must be retested on rating skills every 6 months during the study. Throughout the study raters remain blinded to patient group assignment, and all patients are required to wear a head and arm covering to prevent unblinding of evaluators. Patients are instructed not to discuss group assignment with the rater.
Primary Endpoint
The primary outcome assessment is measured 4 weeks following rehabilitation treatment. The principal measure of success employed in this study is the combined change in the UEFM and the arm motor ability test (AMAT).
Upper Extremity Fugl-Meyer Score. The UEFM is a measure of upper limb motor impairment that quantifies voluntary motor control in relation to the typical evolving synergy patterns experienced by people with stroke as described by Twitchell. 44 In particular, the UEFM assesses components of movement in shoulder, elbow, forearm, and hand including active range of motion, strength, coordination, and hypertonia. Each of the 33 tasks is scored on a 3-point scale as 0, the task cannot be performed; 1, the task is performed partially; or 2, the task is performed flawlessly. The only exception to this scoring is reflex activity, which is scored 0 (absent) or 2 (present). A maximum score on the UEFM is 66 points. The validity and reliability of the UEFM has been demonstrated [45] [46] [47] [48] and is considered a good measure of motor impairment in stroke research. 49 For the purpose of this study, an improvement of 4.5 points in the mean or median UEFM score from baseline measure to 4-week follow-up posttreatment is considered clinically meaningful. This represents a 12% improvement over the average baseline UEFM in the anticipated sample and exceeds the UEFM improvements seen in other published studies of chronic stroke patients. [50] [51] [52] [53] Arm Motor Ability Test. The AMAT is a test of upper limb functional use originally designed to assess limitations in arm and hand use for the purpose of studying learned nonuse and constraint-induced movement therapy. 35 It measures performance on 13 compound tasks, and scores 1 to 3 component skills within each, for a total of 28 component tasks. Ten of the component tasks require bilateral hand use. Each component task is timed with a limit of 1 to 2 minutes. Performance is scored on two domains: functional ability and quality of movement. Functional ability is scored as 0, no use; 1, very slight use; 2, slight use; 3, moderate use; 4, almost normal use; 5, normal use. Quality of movement is scored as 0, no use; 1, very poor; 2, poor; 3, fair; 4, almost normal; 5, normal. The total score is calculated as the mean score on all 28 component tasks for both the functional ability and the quality of movement domains. Yozbatiran et al 35 have shown that the correlation between functional ability and quality of movement are near unity and suggested that the functional ability domain could be used alone for assessment of functional limitations. The normalized AMAT score ranges continuously between 0 and 5. For the purpose of this study, an improvement in AMAT functional ability score of 0.21 points from baseline measure to 4-week follow-up posttreatment is considered clinically meaningful, which correlates with the previously defined clinically meaningful improvement in UEFM. 54
Primary Outcome
The primary outcome measure for success is based on the combined change in UEFM and AMAT from baseline to 4 weeks following rehabilitation therapy. UEFM change is calculated for each patient using the mean of 2 measurements, or the median of 3 measurements at baseline and 4-week follow-up as previously described. A successful outcome for an individual subject is defined as reaching the target changes in both the UEFM score of 4.5 points and in the AMAT of 0.21 points. If the rate of success at 4-week follow-up in the investigational group exceeds the rate of success of the control group by an absolute value of 20%, then epidural CS will be considered efficacious.
Secondary Outcomes
Several secondary outcomes are also measured at follow-up. The proportion of patients achieving target improvement in either the UEFM or AMAT as well as mean change in scores at weeks 1, 4, 12, and 24 are evaluated. Additional measures are collected as listed in Table 3 .
The box-and-block test 34, 47 is a quantifiable measure of skilled control, grasp, and release of objects and is measured at baseline and at follow-up weeks 1, 4, 12, and 24. Grip strength using a standard dynamometer is measured at the same time periods.
The Canadian Occupational Performance Measure (COPM) is intended to measure changes in a patient's perceived occupational performance over time. 36 The COPM is client centered in that the patient selects the 5 most important activities that they are challenged to perform independently. The patient then scores how difficult each item is to perform and their satisfaction with performance on a 10-point scale. The COPM is reproducible, valid, and reliable in patients with stroke. 55, 56 In the Everest Trial, 2 of the 5 selected items from COPM are practiced during the 6-week rehabilitation protocol. The COPM is collected at baseline and then at 1-week follow-up. Changes in COPM will be compared between investigational and control groups.
The ADL subsection of the Stroke Impact Score (SIS) is a self-reported measure of performance on common daily selfcare activities, including cutting food, dressing, toileting, bathing, homemaking, shopping, and managing finances. The SIS is a stroke-specific measure that has been validated and is reliable and sensitive to change. 37 The SIS is collected at baseline and at weeks 4, 12, and 24 following treatment protocol. A comparison of change in the ADL subsection of the SIS between investigational and control groups will be an additional secondary outcome.
Quality-of-life measures will include the score from the quality-of-life subsection of the SIS, the Stroke Specific Quality-of-Life Scale, 40 
Safety Outcomes
Medical complications are carefully monitored and recorded throughout the intervention and follow-up periods. Care is taken to prevent medical problems during the protocol as described in the investigational procedures. In particular, complications associated with the implant and explant surgical procedures are monitored and carefully recorded. Use of the stimulation system throughout the study is monitored for adverse effects. Finally, any complications associated with other activities of the investigational protocol, such as the rehabilitation training, fMRI procedures, and outcome assessments, are recorded. Although all adverse events will be reported, Table 5 lists representative relevant events.
Data Entry and Management

Case Report Forms
Completed and signed case report forms are faxed to the central monitoring site (Northstar Neuroscience, Inc) for entry into the study database. During site visits, the source documents are checked against the faxed copies.
Data Safety Monitor Board
The Data Safety and Monitoring Board (DSMB) comprises a neurologist, a physiatrist, a neurosurgeon, and a biostatistician. The DSMB meetings occur every 3 to 6 months from enrollment of the first patient until completion of follow-up for the last patient.
Adverse Events
All adverse events are sent to the central monitoring site with serious events being sent within 24 hours of occurrence. Adverse events are classified by the local site investigators according to whether they are anticipated, device related, procedure related, and/or serious. Following review by the sponsor, the events are signed off or clarified with the local site if there are additional questions. The events are entered into a database.
Data Entry and Resolution
Data are double entered into the database by full-time data entry personnel at the central monitoring site. The Clinical Database Management System compares the 2 entries and displays differences for review and resolution. Data are validated by analyzing for missing and discrepant entries using electronic edits as well as manual review. Queries are sent to the sites to clarify unresolved discrepancies. Once responses to queries are received, corrections and updates to data fields are completed in the clinical database.
Monitoring Visits
Regular (every 4 to 6 weeks, depending on number of subjects enrolled) clinical monitoring visits are conducted by appropriately trained clinical research associates. To ensure that investigators and their staff understand and accept their defined responsibilities, the monitor maintains regular correspondence and performs periodic site visits during the course of the study to verify the continued acceptability of the facilities, compliance with the research protocol, complete documentation and reporting of any complications and unanticipated adverse device effects, and the maintenance of complete records. Clinical monitoring includes review and resolution of missing or inconsistent data and source document checks (ie, comparison of submitted study data to original reports) to assure data accuracy.
As required by the Investigational Device Exemp tion regulations, the conduct and monitoring of the clinical investigation are conducted in accordance with the study sponsor's internal procedures. This includes obtaining and maintaining all required investigator and institutional review board documentation, investigational site visits and monitoring, control of device shipment and disposition, review and maintenance of case report forms and investigational files, and compliance with reporting requirements and monitoring of the investigators' adherence to the research protocol.
Data Analysis Statistical Analysis
Prior to performing analyses, the statistical assumptions required for conducting the particular statistical analyses will be confirmed. Demographic information including age, sex, time since index stroke, side of stroke lesion, and baseline measures for outcome variables will be compared between investigational and control patients using standard statistical techniques. All analyses will be conducted using SAS (SAS Institute, Cary, NC).
Table 5 Potential Adverse Events Associated With Placement, Use, and Removal of the Epidural Cortical Stimulation System Monitored During the Clinical Trial
Headache or neck pain Partial or generalized seizures associated with stimulation Induction of a seizure disorder Induction of motor fasciculations Neurological decline due to electrode placement or stimulation (≥20% decline from baseline UEFM score) Infection, bleeding, or hematoma associated with incision sites, IPG, or electrodes Clinically significant pain at any incision site Wound dehiscence Clinically significant epidural or subdural bleeding or fluid collection Increased intracranial pressure Clinically significant tissue erosion related to electrode, lead, or IPG Brain hemorrhage or ischemic injury associated with electrode placement resulting in paralysis, coma, or death Clinically significant CSF leak Movement, migration, fracture/malfunction, or extrusion of electrode, lead, or IPG Foreign body tissue reaction to implants or other medical materials (eg, surgical tape) Damage to nerves or vasculature at surgical sites Formation of fibrous tissue or pockets of fluid Neural tissue damage Medical morbidity including myocardial infarction, pneumonia, or venous thromboembolism Death Anesthesia-associated reactions (nausea, vomiting, fever, hypoxia, pneumonia, adverse drug reaction, urinary retention, or death) Surgical risks associated with electrode and IPG placement or removal (unstable blood pressure, vertigo, dizziness/lightheadedness, swelling, or seizure)
Abbreviations: UEFM, upper extremity Fugl-Meyer; IPG, implantable pulse generator; CSF, cerebrospinal fluid.
The primary endpoint analysis will be conducted on the basis of intent to treat and per protocol. The efficacy of the intervention will be tested by comparing the proportion of patients in the investigational group achieving success with those in the control group. A z score will be calculated according to the following formula:
where πAE C and πAE I are the estimated proportions of control and investigational subjects, respectively, who have a clinically meaningful improvement on measured UEFM and AMAT from baseline to follow-up week 4. For testing efficacy, a one-sided test will be used such that a z score greater than 1.96 (z α with α = .025) will be considered statistically significant. The more conservative type I error of 0.025, which is half the conventional type I error used in two-sided tests, was chosen as recommended by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 59 Secondary analyses will compare mean changes in UEFM, AMAT, and box-and-block test between investigational and control groups at 1, 4, 12, and 24 weeks posttreatment using repeated-measures models that accommodate the nonindependence of observations for subjects and allow for the comparison of outcomes between treatment groups during the study period and at specific time points (repeated-measures analysis of variance). Covariates considered for inclusion in the models are age, sex, baseline assessment scores, time since index stroke, location of lesion, size of lesion, side of stroke lesion, and hand dominance.
To assess for a decline in performance postoperatively, baseline and postoperative (prerehabilitation) scores on UEFM will be compared by one-tailed t test at α = .025. A 20% decline from baseline will be considered clinically significant. Adverse events will be summarized according to incidence within the population. Incidence of specific adverse events in each treatment group will be calculated as the number of subjects experiencing the adverse event divided by the number of subjects in the respective treatment group. Exact binomial 95% confidence intervals on the proportion of subjects reporting specific events in each treatment group will be presented for comparison.
Sample Size Determination
The sample size for the Everest Trial was determined from primary efficacy endpoint and safety requirements. The estimate for efficacy is based on a comparison of 2 independent proportions with continuity correction simplified by assuming the most conservative population proportions:
where δ is the minimum clinically meaningful difference between proportions. The sample size was calculated using a one-sided significance level of .025 (z α = 1.96), an 80% power (z β = 0.842), and an ability to detect a 30% difference between the rate of success in each group. With these assumptions, the trial requires 51 patients per treatment group to demonstrate efficacy. For safety, a binomial model was used to estimate the likelihood of observing at least 1 adverse event with at least a .95 probability when that event has at least a .03 probability of occurring. This estimate requires 100 patients receiving investigational treatment. Thus, 100 investigational treatment patients and 51 control patients are estimated. To account for patient attrition during the study, up to 110 patients will be randomized to the investigational group and up to 64 participants to the control group in a roughly 2:1 ratio.
Discussion
Electrical stimulation of the cerebral cortex is gaining interest in the treatment of several medical conditions including central pain, focal dystonia, epilepsy, various movement disorders including Parkinson's disease, and psychiatric disorders such as depression. [60] [61] [62] [63] [64] [65] [66] [67] The use of CS to treat stroke-related motor deficits has focused primarily on upper limb motor control because the prognosis for recovery of arm and hand function after stroke remains limited. Second, the cortical representation of hand and fingers has a proportionally large somatotopy over the lateral convexity of the M1 cortex and the surrounding regions, making them easily accessible to treatments that employ CS technology.
The technology used in the Everest Clinical Trial requires surgical implantation of an epidural electrode through a small craniotomy and a pulse generator implanted in the chest wall. An advantage of a totally implantable system is the ability to consistently and reliably target CS to the region of cortex that is involved with producing movement of the affected hand. The fixed position of the electrode allows delivery of continuous subthreshold stimulation during rehabilitation therapy, leaving the patient mobile and free of external hardware. Although isolated CS at rest can enhance cortical excitability and influence learning following stimulation, evidence suggests that long-lasting and experience-specific neuroplastic changes occur when brain stimulation is paired with an environmental stimulus. [67] [68] [69] An implanted system that provides continuous targeted stimulation during focused rehabilitation training should enhance efficacy and perhaps result in longer-term functional improvement. In contrast, noninvasive CS using rTMS would be cumbersome to apply during task-specific therapy in a clinical setting. Although tDCS may be deliverable during active therapy, targeting the electrode for each treatment would be a challenge.
The Everest Clinical Trial uses a randomized single-blinded study design with objective measures for primary endpoints. Although subjective secondary endpoints are also used in the study, the objective primary outcome measures are collected n > 0:5
using rigorous blinding procedures, and from a relatively large sample, reducing the risk of bias in this study. Furthermore, the larger number of patients randomized to the investigational group enhances the evaluation of safety of the implantable system. The Everest study is conducted without a sham surgery group included in the design for scientific and ethical reasons. Determining safety in a clinical trial of a novel device is mandatory and supersedes standards for research design. 70 Once the safety of implanted epidural CS has been delineated, a placebo controlled neurosurgical trial may be permissible; however, some controversy still exists over the need for sham neurosurgery in clinical research. [70] [71] [72] Although sham surgery has been used to evaluate cell implantation for Parkinson's disease, there are no clear recommendations or guidelines for when sham surgery is necessary to prove efficacy of a treatment. Furthermore, Macklin 70 has raised several ethical concerns about the risk-to-benefit profile of sham surgery in clinical research.
Without a surgical control group, many would consider the risk of a placebo effect in the investigational group to be high. But, in a meta-analysis of clinical trials comparing placebo medications with no treatment, Hróbjartsson and Gøtzsche 73 noted that the placebos had no measurable effect in studies using objective measures and binary outcomes. The main outcome in the Everest Trial is both objective and binary. Both the UEFM score and the AMAT are measured by a blinded rater and no subjective reports by the patient regarding functional arm use are included in the main outcome. The main outcome is binary, calculated as the percentage of patients in each group achieving success as determined by the magnitude of change in these measures from baseline to the 4-week posttreatment assessment. Furthermore, the definition of success requires achieving predefined target changes in both UEFM and AMAT, making the possibility of a measurable placebo effect unlikely if the null hypothesis is true. 73 Defining success in a clinical trial based on the combined performance on 2 measures is a unique approach and has not been previously employed in rehabilitation research. If CS has an effect on cortical neuroplasticity during motor learning, it would be expected that improvements in motor control could be measured as a reduction in motor impairment. However, any clinically useful intervention in rehabilitation must improve functional performance to be truly meaningful. Defining success as achieving clinically meaningful changes in both impairment and functional use, as measured by UEFM and AMAT, respectively, adds scientific rigor to this study and is a novel approach in rehabilitation research. Although such an approach has not been previously employed, it is entirely consistent with recent global efforts to define disability along the dimensions of the International Classification of Functions, Disability, and Health (ICF) in large part because of its acceptance by the broader community of health care professionals and its greater research potential to identify important interactions and links between outcome measures. 74 The ICF was approved in May 2001 by the World Health Assembly and is the successor to the International Classification of Impairments Disabilities and Handicaps. Using rules that specify links between items from specific instruments and corresponding ICF categories, 75 the representation of ICF components of body functions and structures, activities, participation, and contextual factors can be investigated. The ICF is currently being applied in the clinical research and clinical practice areas including rehabilitation medicine. 76 The ICF classification is an effective organizational framework to allow assessment of outcome interactions that are associated with health-related problems (ie, body function/structure impairments, activity limitations, participation restrictions) and across disease-specific or injury-specific health conditions. 74 At present, there is no published criterion for clinically meaningful change in either the UEFM or AMAT in patients with chronic hemiplegia. Although these 2 domains are not independent of one another, the combined outcome measure evaluates whether the rehabilitation intervention under study improves both motor control and functional use in the affected upper limb. Patients in this study will not achieve success unless they meet target criteria in both domains. The target criteria of 4.5 points for change from baseline to 4 weeks posttreatment on UEFM score was selected based on outcomes from other blinded studies of rehabilitation interventions for patients with chronic stroke. The pooled results of 4 clinical trials of different rehabilitation interventions for patients with moderately severe chronic hemiplegia show a mean gain of 2.68 points on the UEFM. [50] [51] [52] [53] For the purpose of the Everest Trial, a larger improvement of 4.5 points was chosen, which is approximately equal to a 12% gain over the average baseline value for this patient population. To assure that UEFM measures reflect true upper limb motor impairment, multiple measures are performed at baseline and 4 weeks after end of treatment, and rater's skill level will be monitored and confirmed regularly. An improvement of 4.5 points in UEFM is on the average associated with a 0.21 point improvement in the normalized AMAT. 54 In the Everest Trial, patients achieving success must reach these target changes on both measures to be considered clinically meaningful.
Detailed measures of upper limb and trunk kinematics during functional tasks using modern motion analysis technology could add valuable information to this study. However, because of limited availability of motion analysis equipment and expertise, kinematic measures are difficult to collect in large multicenter trials. If the Everest Trial demonstrates efficacy of CS, kinematic measurements will be an important next step.
The Everest Trial will produce the largest collection of fMRI data before and after a rehabilitation intervention. The imaging data will provide a rich source for research on the mechanism of recovery and neuroplastic changes in humans with stroke. The particular effects of CS on changes in cortical and subcortical activity will be of particular interest in this study, but the data obtained from the control group will provide additional important information about the effects of an intense and focused motor relearning and rehabilitation therapy program on brain activity following stroke. The fMRI BOLD signal in the peri-Rolandic region of the ipsilesional cortex is used to target the location of the cortical electrode. Whether the BOLD signal seen represents cortical excitation associated with hand movement remains controversial. [77] [78] [79] We assume only that the BOLD signal represents an area of activation for surgical guidance. Analysis of fMRI data following the clinical trial will shed further light on the use of fMRI for targeting CS.
The rehabilitation protocol incorporates modern task-oriented therapeutic techniques and includes a daily focus on both prefunctional (impairment and structural level) and functional activities. The program is well defined and adhered to by trained therapists who are regularly recertified on the protocol throughout the study. The Everest Trial will permit the evaluation of the protocol's efficacy independent of CS through analysis of the control group.
Conclusion
The Everest Clinical Trial is the first pivotal randomized control clinical trial of the safety and efficacy of direct CS delivered during rehabilitation for recovery of upper limb use in patients with ischemic stroke. In addition to determining if CS is a safe and effective modality when combined with evidence-based rehabilitation training, the data from this study will enhance our understanding of the effects of taskoriented therapy in chronic stroke patients using fMRI technology and the degree to which neuroplasticity is influenced by rehabilitation alone or when combined with CS.
